ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BCMA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells. When CD3 is engaged on a T cell, it turns the T-cell on and makes it kill whatever cell triggered the activation. Because ABBV-383 sticks very strongly to the BCMA on your myeloma cells, nearby T-cells should specifically attack your tumor cells.
This study is open-label, meaning that everyone on the study will receive ABBV-383. It is a Phase 1, First-in-Human trial, meaning that it is the first study where ABBV-383 will be given to human patients. ABBV-383 is an investigational agent, meaning that it is still being tested for safety and efficacy and has not yet been approved by the FDA.
The purpose of the Study is:
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Read the latest news and updates on this trial.